Abstract:BackgroundSeveral studies implicated that lung cancer progression was governed by the interaction between estrogen receptor (ER) and epidermal growth factor receptor (EGFR) signaling pathways. Combined targeting of EGFR and ER may have the synergistic effect in lung cancer treatment. The aim of this study was to explore the potential utility of inhibiting these two pathways with combination of anastrozole and gefitinib in non-small cell lung cancer (NSCLC) cell lines.Materials and methodsThe expression levels of ER (ER-α and ER-β) in lung cancer cell lines (A549, H460, SPC-A-1, H1299) and normal bronchus epithelial cell BEAS-2B were detected using real-time PCR and Western blot. Immunocytochemistry was used to locate ER-α and ER-β in cell line with highest ER expression levels. The cells were treated with anastrozole or gefitinib alone or in combination. The cell proliferation inhibition was detected by the CCK8 assay, cell cycle and apoptosis effects were detected by flow cytometry; the expression levels of phosphorylated-EGFR (p-EGFR), ERK, phosphorylated-ERK (p-ERK), AKT and phosphorylated-AKT (p-AKT) were detected by Western blot.ResultsAmong these cell lines the expression levels of ER in A549 cells were highest. In A549 cell line, ER-α was mainly localized in the cytoplasm, whereas ER-β was mainly localized in the cytoplasm and to a lesser degree in the nucleus. The combination of two drugs increased the proliferation inhibition rates for 24h, 48h, 72h to 37.66±1.02%, 63.41±2.02%, 70.50±0.86%, respectively, which was closely associated with elevation of the G0/G1 phase fraction (P<0.05). Apoptosis rates of A549 cells treated with anastrozole, gefitinib alone or in combination were 10.72±1.12%, 17.40±1.28%, 23.02±2.32%, respectively (P<0.05). The synergistic effects of the combination therapy were accompanied by reduction of p-EGFR, p-ERK and p-AKT expression compared with individual treatment.ConclusionsThe results of this study suggest that the combination of anastrozole and gefitinib compared with either drug alone can maximally inhibit cell proliferation, induce apoptosis, and affect downstream signaling pathways. Our study supports functional interaction between the ER and the EGFR pathways in lung cancer and provides a clinically exploitable strategy for non-small cell lung cancer patients.

Combination of Cetuximab and Gefitinibto Therapy Non-Small Cell Lung Cancer(nsclc) in Vitro

Effects of Anti-Egfr Monoclonal Antibody Cetuximab in Combination with the EGFR Tyrosine Kinase Inhibitor Gefitinib on Apoptosis of Human Pulmonary Adenocarcinoma Cells and Their Action Mechanism

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

Combined Targeting Of The Estrogen Receptor And The Epidermal Growth Factor Receptor In Non-Small Cell Lung Cancer Shows Enhanced Antiproliferative Effects

Combination of S-1 and Gefitinib Increases the Sensitivity to Radiotherapy in Lung Cancer Cells

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

Research Advancement on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Combined with Chemotherapy in Treatment of Non-Small Cell Lung Cancer

Cetuximab-conjuated Gold Nanoparticles for the Therapy of Non-Small Cell Lung Cancer

Apatinib to Enhance Antitumor Activity of Gefitinib in Non-Small Cell Lung Cancer.

Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib

A Novel Strategy of EGFR‑TKI Combined Chemotherapy in the Treatment of Human Lung Cancer with EGFR‑sensitive Mutation.

Synergistic Effect of Gefitinib and Cisplatin on Proliferation of Lung Cancer Cell Line

[Effects of Monoclonal Antibody Cetuximab on Proliferation of Non-Small Cell Lung Cancer Cell Lines].

EP1.03-11 Mechanisms of Gefitinib Plus Pemetrexed on Human Non-Small Cell Lung Cancer

The Synergistic Effect of EGFR Tyrosine Kinase Inhibitor Gefitinib in Combination with Aromatase Inhibitor Anastrozole in Non-Small Cell Lung Cancer Cell Lines

In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.

Combined Tamoxifen and Gefitinib in Non-Small Cell Lung Cancer Shows Antiproliferative Effects.

Clinical Efficacy Of Egfr-Tkis In Combination With Chemotherapy In Patients With Advanced Non-Small Cell Lung Cancer Harboring Egfr Mutations

Antiproliferative Effects on Non-Small Cell Lung Cancer Cells by Combining Tamoxifen and Gefitinib

Inhibition of DNA‑PK by Gefitinib Causes Synergism Between Gefitinib and Cisplatin in NSCLC